PT1562955E - Derivados de quinazolina como inibidores da scr tirosina-cinase - Google Patents

Derivados de quinazolina como inibidores da scr tirosina-cinase Download PDF

Info

Publication number: PT1562955E
Authority: PT; Portugal
Prior art keywords: tyrosine kinase; kinase inhibitors; quinazoline derivatives; src tyrosine; src
Prior art date: 2002-11-04

Application number

PT03769689T

Other languages

English (en)

Inventor

Patrick Ple

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-04

Filing date

2003-10-29

Publication date

2008-05-05

2003-10-29 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-05-05 Publication of PT1562955E publication Critical patent/PT1562955E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT03769689T 2002-11-04 2003-10-29 Derivados de quinazolina como inibidores da scr tirosina-cinase PT1562955E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02292736		2002-11-04
EP03290900		2003-04-10

Publications (1)

Publication Number	Publication Date
PT1562955E true PT1562955E (pt)	2008-05-05

Family

ID=32313852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT03769689T PT1562955E (pt)	2002-11-04	2003-10-29	Derivados de quinazolina como inibidores da scr tirosina-cinase

Country Status (27)

Country	Link
US (1)	US7462623B2 (pt)
EP (1)	EP1562955B1 (pt)
JP (2)	JP4593464B2 (pt)
KR (1)	KR101089462B1 (pt)
AR (1)	AR041884A1 (pt)
AT (1)	ATE387451T1 (pt)
AU (1)	AU2003278383B2 (pt)
BR (1)	BR0315756A (pt)
CA (1)	CA2503371C (pt)
CO (1)	CO5560578A2 (pt)
CY (1)	CY1108061T1 (pt)
DE (1)	DE60319410T2 (pt)
DK (1)	DK1562955T3 (pt)
EG (1)	EG24957A (pt)
ES (1)	ES2300619T3 (pt)
IL (1)	IL168013A (pt)
IS (1)	IS2568B (pt)
MX (1)	MXPA05004858A (pt)
MY (1)	MY137835A (pt)
NO (1)	NO331951B1 (pt)
NZ (1)	NZ539408A (pt)
PL (1)	PL215161B1 (pt)
PT (1)	PT1562955E (pt)
RU (1)	RU2350618C2 (pt)
SI (1)	SI1562955T1 (pt)
TW (1)	TWI320786B (pt)
WO (1)	WO2004041829A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1521747B1 (en)	2002-07-15	2018-09-05	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
SI2392564T1 (sl)	2003-09-26	2014-02-28	Exelixis, Inc.	c-Met modulatorji in postopki uporabe
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0427697D0 (en)	2004-12-17	2005-01-19	Astrazeneca Ab	Chemical process
WO2009068906A2 (en) *	2007-11-26	2009-06-04	Astrazeneca Ab	Combinations comprising zd4054 and a src family kinase inhibitor 172
MX2011007620A (es)	2009-01-16	2011-11-04	Exelixis Inc	Sal de malato de n(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n '-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PT2621481T (pt)	2010-09-27	2019-11-19	Exelixis Inc	Inibidores duplos de met e vegf para o tratamento de cancro da próstata resistente à castração e metástases ósseas osteoblásticas
AR092289A1 (es) *	2011-11-14	2015-04-15	Sunshine Lake Pharma Co Ltd	Derivados de aminoquinazolina y sus sales y metodos de uso
KR20180086187A (ko)	2015-10-05	2018-07-30	더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕	자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
WO2017156350A1 (en)	2016-03-09	2017-09-14	K-Gen, Inc.	Methods of cancer treatment
PL3849534T3 (pl)	2018-09-10	2025-05-12	Mirati Therapeutics, Inc.	Połączenie dazatynibu i adagrasibu do stosowania w leczeniu niedrobnokomórkowego raka płuca
CN119504612A (zh) *	2024-11-18	2025-02-25	中国海洋大学	一种喹唑啉茋类衍生物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) *	1991-05-10	1997-12-16	Rhone Poulenc Rorer Int	Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
PT100905A (pt)	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
GB9205320D0 (en) *	1992-03-11	1992-04-22	Ici Plc	Anti-tumour compounds
GB9323290D0 (en)	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US6046206A (en)	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CN1125817C (zh)	1996-02-13	2003-10-29	曾尼卡有限公司	作为vegf抑制剂的喹唑啉衍生物
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
JP4464466B2 (ja)	1996-03-05	2010-05-19	アストラゼネカ・ユーケイ・リミテッド	４―アニリノキナゾリン誘導体
US6514971B1 (en)	1996-03-15	2003-02-04	Zeneca Limited	Cinnoline derivatives and use as medicine
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
ID19609A (id)	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
ATE300521T1 (de)	1996-09-25	2005-08-15	Astrazeneca Ab	Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
DE69838172T2 (de)	1997-08-22	2008-04-10	Astrazeneca Ab	Oxindolylchinazolinderivate als angiogenesehemmer
ES2211175T3 (es)	1998-09-29	2004-07-01	Wyeth Holdings Corporation	Inhibidores de proteinas de tipo tirosina quinasas a base de 3-cianoquinolinas sustituidas.
BR9914326A (pt)	1998-10-08	2001-06-26	Astrazeneca Ab	Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou de redução da permeabilidade vascular em animais de sangue quente em necessidade de um tal tratamento
SK288365B6 (sk)	1999-02-10	2016-07-01	Astrazeneca Ab	Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
CN1391561A (zh)	1999-09-21	2003-01-15	阿斯特拉曾尼卡有限公司	喹唑啉化合物和含有喹唑啉化合物的药物组合物
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
IL149034A0 (en)	1999-11-05	2002-11-10	Astrazeneca Ab	Quinazoline derivatives as vegf inhibitors
EP1272185B1 (en)	2000-03-06	2005-07-27	AstraZeneca AB	Use of quinazoline derivatives as angiogenesis inhibitors
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
AU779695B2 (en)	2000-04-07	2005-02-10	Astrazeneca Ab	Quinazoline compounds
UA73993C2 (uk) *	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
ES2317923T3 (es)	2000-08-09	2009-05-01	Astrazeneca Ab	Compuestos de cinolina.
JP2004505965A (ja)	2000-08-09	2004-02-26	アストラゼネカ　アクチボラグ	化合物
EP1313726A1 (en)	2000-08-09	2003-05-28	AstraZeneca AB	Quinoline derivatives having vegf inhibiting activity
US7115615B2 (en)	2000-08-21	2006-10-03	Astrazeneca	Quinazoline derivatives
EP1326860A1 (en)	2000-10-13	2003-07-16	AstraZeneca AB	Quinazoline derivatives
EP1326859A1 (en)	2000-10-13	2003-07-16	AstraZeneca AB	Quinazoline derivatives with anti-tumour activity
EP1332141A1 (en)	2000-10-25	2003-08-06	AstraZeneca AB	Quinazoline derivatives
ES2312557T3 (es)	2001-04-19	2009-03-01	Astrazeneca Ab	Derivados de quinazolina.
WO2002092577A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2002092579A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	4-anilinoquinazoline derivatives
WO2002092578A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
JP4326328B2 (ja)	2001-07-16	2009-09-02	アストラゼネカアクチボラグ	キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
WO2003047582A1 (en)	2001-12-05	2003-06-12	Astrazeneca Ab	Quinoline derivatives as antitumour agents
KR101093345B1 (ko)	2002-02-01	2011-12-14	아스트라제네카 아베	퀴나졸린 화합물
GB0215823D0 (en)	2002-07-09	2002-08-14	Astrazeneca Ab	Quinazoline derivatives
EP1528925B1 (en)	2002-07-09	2009-04-22	Astrazeneca AB	Quinazoline derivatives for use in the treatment of cancer
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
BR0313116A (pt)	2002-08-09	2005-07-05	Astrazeneca Ab	Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como humano, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável.
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
GB0226434D0 (en)	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
JP2006517575A (ja)	2003-02-13	2006-07-27	アストラゼネカアクチボラグ	組合せ療法
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent

2003
- 2003-10-29 AU AU2003278383A patent/AU2003278383B2/en not_active Ceased
- 2003-10-29 NZ NZ539408A patent/NZ539408A/en not_active IP Right Cessation
- 2003-10-29 DK DK03769689T patent/DK1562955T3/da active
- 2003-10-29 SI SI200331192T patent/SI1562955T1/sl unknown
- 2003-10-29 ES ES03769689T patent/ES2300619T3/es not_active Expired - Lifetime
- 2003-10-29 CA CA2503371A patent/CA2503371C/en not_active Expired - Fee Related
- 2003-10-29 KR KR1020057007855A patent/KR101089462B1/ko not_active Expired - Fee Related
- 2003-10-29 PT PT03769689T patent/PT1562955E/pt unknown
- 2003-10-29 EP EP03769689A patent/EP1562955B1/en not_active Expired - Lifetime
- 2003-10-29 JP JP2005502127A patent/JP4593464B2/ja not_active Expired - Fee Related
- 2003-10-29 US US10/533,931 patent/US7462623B2/en not_active Expired - Fee Related
- 2003-10-29 BR BR0315756-3A patent/BR0315756A/pt not_active IP Right Cessation
- 2003-10-29 DE DE60319410T patent/DE60319410T2/de not_active Expired - Lifetime
- 2003-10-29 AT AT03769689T patent/ATE387451T1/de active
- 2003-10-29 MX MXPA05004858A patent/MXPA05004858A/es active IP Right Grant
- 2003-10-29 RU RU2005117337/04A patent/RU2350618C2/ru not_active IP Right Cessation
- 2003-10-29 PL PL376255A patent/PL215161B1/pl unknown
- 2003-10-29 WO PCT/GB2003/004703 patent/WO2004041829A1/en not_active Ceased
- 2003-10-30 TW TW092130284A patent/TWI320786B/zh not_active IP Right Cessation
- 2003-11-03 MY MYPI20034197A patent/MY137835A/en unknown
- 2003-11-04 AR ARP030104036A patent/AR041884A1/es not_active Application Discontinuation
2005
- 2005-04-13 IL IL168013A patent/IL168013A/en not_active IP Right Cessation
- 2005-04-19 NO NO20051900A patent/NO331951B1/no not_active IP Right Cessation
- 2005-04-30 EG EGNA2005000178 patent/EG24957A/xx active
- 2005-05-03 CO CO05042313A patent/CO5560578A2/es not_active Application Discontinuation
- 2005-05-19 IS IS7849A patent/IS2568B/is unknown
2008
- 2008-04-24 CY CY20081100460T patent/CY1108061T1/el unknown
2010
- 2010-07-26 JP JP2010167576A patent/JP2010270143A/ja active Pending

Also Published As

Publication number	Publication date
NO20051900L (no)	2005-06-01
RU2005117337A (ru)	2006-01-20
MY137835A (en)	2009-03-31
KR20050074526A (ko)	2005-07-18
RU2350618C2 (ru)	2009-03-27
EP1562955B1 (en)	2008-02-27
AU2003278383A1 (en)	2004-06-07
DE60319410D1 (en)	2008-04-10
KR101089462B1 (ko)	2011-12-07
CY1108061T1 (el)	2014-02-12
CA2503371A1 (en)	2004-05-21
SI1562955T1 (sl)	2008-06-30
AR041884A1 (es)	2005-06-01
JP4593464B2 (ja)	2010-12-08
IL168013A (en)	2013-03-24
EG24957A (en)	2011-02-28
AU2003278383B2 (en)	2007-06-14
CO5560578A2 (es)	2005-09-30
WO2004041829A1 (en)	2004-05-21
NO331951B1 (no)	2012-05-14
TWI320786B (en)	2010-02-21
US7462623B2 (en)	2008-12-09
PL215161B1 (pl)	2013-10-31
PL376255A1 (en)	2005-12-27
IS2568B (is)	2010-01-15
DE60319410T2 (de)	2009-02-19
JP2006506463A (ja)	2006-02-23
NZ539408A (en)	2007-09-28
DK1562955T3 (da)	2008-06-02
US20060122199A1 (en)	2006-06-08
HK1079195A1 (en)	2006-03-31
MXPA05004858A (es)	2005-07-22
CA2503371C (en)	2011-01-11
IS7849A (is)	2005-05-19
EP1562955A1 (en)	2005-08-17
ATE387451T1 (de)	2008-03-15
TW200420567A (en)	2004-10-16
JP2010270143A (ja)	2010-12-02
BR0315756A (pt)	2005-09-06
ES2300619T3 (es)	2008-06-16

Publication	Publication Date	Title
IL174261A0 (en)	2006-08-01	Quinazoline derivatives as tyrosine kinase inhibitors
IL174258A0 (en)	2006-08-01	Quinazoline derivatives as tyrosine kinase inhibitors
IL173200A0 (en)	2006-06-11	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
AU2003299651A8 (en)	2004-06-30	Tyrosine kinase inhibitors
AU2003233455A1 (en)	2003-10-13	Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
AU2003298942A8 (en)	2004-06-30	Tyrosine kinase inhibitors
AP2003002781A0 (en)	2003-06-30	Quinolinone derivatives as tyrosine kinase inhibitors
AU2003282891A8 (en)	2004-04-23	Novel tyrosine kinases inhibitors
ATE446093T1 (de)	2009-11-15	Substituierte chinazolin-derivate als aurora- kinase inhibitoren
EP1581539A4 (en)	2007-09-19	NEW TYROSINE KINASE HEMMER
AU2003275282A8 (en)	2004-04-23	Novel tyrosine kinase inhibitors
IL173593A0 (en)	2006-07-05	Quinazoline analogs as receptor tyrosine kinase inhibitors
IL184798A0 (en)	2007-12-03	Quinazoline derivatives as tyrosine kinase inhibitors
PL376255A1 (en)	2005-12-27	Quinazoline derivatives as src tyrosine kinase inhibitors
IL173484A0 (en)	2006-06-11	Quinazoline derivatives as angiogenesis inhibitors
SI1660090T1 (sl)	2013-02-28	Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
AU2002253350A1 (en)	2002-11-11	4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
GB0201384D0 (en)	2002-03-13	Tyrosine kinase inhibitors
IS8386A (is)	2006-03-30	Kínasólínafleiður sem týrósínkínasatálmar
HK1090052A (en)	2006-12-15	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
HK1112903A (en)	2008-09-19	Quinazoline derivatives as tyrosine kinase inhibitors
HK1122563A (en)	2009-05-22	4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
AU2003237902A1 (en)	2003-09-02	Tyrosine kinase inhibitors
SI1684750T1 (sl)	2010-09-30	aminoariloksazolne spojine kot inhibitorji tirozin kinaze